Prospective Randomized Clinical Trial for Effect of Stellate Ganglion Block in Medically Refractory Ventricular Tachycardia
试验速览
- 阶段
- 不适用
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Duration of VT/VF episodes after randomization
研究概览
简要总结
The investigators will compare the effects of PSGB(percutaneous stellate ganglion block) in patients with recurrent sustained VT/VF in spite of appropriate medical therapy and cardio-version/ defibrillation after correction of underlying correctable factors with those without PSGB by prospective randomized trail. PSGB will be performed every 3 days by anesthesiology specialist after cardiologist's request, until the stabilization of VT/VF. We will compare the frequency and episode number of VT/VF, procedure related complication, acute and long-term mortality.
详细描述
Recurrent ventricular tachycardia(VT)/ fibrillation(VF) increases mortality, especially in patients with structural heart disease. It has been reported that cardiac sympathectomy reduces VT/VF episodes in patients with complex VT, long QT syndrome, catecholaminergic polymorphic VT, or myocarditis. However, cardiac sympathectomy operation is hard to conduct in patients with hemodynamically unstable recurrent VT/VF or electrical storm. Therefore, we hypothesized that bed-side percutaneous stellate ganglion block (PSGB) reduces VT/VF episodes and mortality in patients with repetitive VT/VF who are properly managed with optimal medical therapies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients agreement of consent
- •AF patient age 20-85
- •Patient are diagnosed Refractory Ventricular tachycardia
- •Patients who have generated Refractory Ventricular tachycardia despite of defibrillation and drug therapy
- •Patients with ICD have generated ICD shock or anti-tachycardia pacing despite of defibrillation and drug therapy
排除标准
- •Patients who do not agree with study inclusion
- •Patients who do not taken stellate ganglion block due to unstable hemodynamic status
- •Patients have experienced major hemorrhagic complication
- •Patients of the DNR status
- •Patients with malignancy tumor, major neurogenic disease or gastrointestinal disease
研究组 & 干预措施
group A+PSGB
(Antiarrhythmic drug + percutaneous stellate ganglion block) group
干预措施: Antiarrhythmic drug (Drug)
group A+PSGB
(Antiarrhythmic drug + percutaneous stellate ganglion block) group
干预措施: percutaneous stellate ganglion block (PSGB) (Procedure)
group A
Antiarrhythmic drug group
干预措施: Antiarrhythmic drug (Drug)
结局指标
主要结局
Duration of VT/VF episodes after randomization
时间窗: 5 days after randomization
Number of VT/VF episodes after randomization
时间窗: 5 days after randomization
次要结局
- mortality(1 month after the enrollment)
- procedure related complication(1 month after the enrollment)